Emergent BioSolutions Looks beyond Biodefence with Trubion Acquisition
By Heather Cartwright
Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)
Published: 28 Sep-2010
DOI: 10.3833/pdr.v2010.i7.1382 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Emergent BioSolutions, best known for its prophylactic anthrax vaccine BioThrax® (anthrax vaccine adsorbed), has acquired Trubion Pharmaceuticals in order to expand its pipeline beyond infectious diseases and into oncology and autoimmune diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS